A Phase 3 interventional study of Peginterferon alfa-2b and Ribavirin in Hepatitis C, Chronic, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-04-04.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.
Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 21st largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2007, is one of 22 in phase 3, and was the 27th registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 3 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 4 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 94 is close to the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 99 across the 39 interventional studies. Of the 35 that completed or were terminated, 21 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
110 studies in Hepatitis C, Chronic by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 106 finished, 81 (76%) have results posted.
Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, this one is the 41st largest by enrollment of the 72 interventional ones that give a count, is one of 10 that started in 2007, is one of 32 in phase 3, and was the 62nd registered.
Merck & Co., Inc’s Hepatitis C, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 110 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study P02538 Part 2 is a 5-year long term follow-up (LTFU) study in pediatric participants who were treated with at least one dose of peginterferon alfa-2b (PEG-IFN) and ribavirin (RBV) and who completed the follow-up in the P02538 Part 1 study (NCT00104052). No study drug therapy will be administered during the P02538 Part 2 study. Durability of virologic response will be assessed for participants who attained sustained virologic response (SVR) in Part I of this study by performing annual Hepatitis C Virus ribonucleic acid (HCV-RNA) testing. In addition, this study will characterize long-term safety in all participants who received PEG-IFN plus RBV treatment.
During the Part 2 LTFU, participants will be evaluated at Years 1, 2, 3, 4, and 5. Each participant's first LTFU visit will be scheduled approximately 1 year after the post-treatment Follow-up Week 24 visit in Part 1 of this study (NCT00104052).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pediatric participants who completed treatment with peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) in P02538 Part 1 of this study (NCT00104052) were enrolled in a 5-year Long Term Follow-Up (LTFU) during P02538 Part 2 (NCT00761735). No study treatment was administered in Part 2.
Biological: Peginterferon alfa-2b · Drug: Ribavirin
In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m\^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
Also known as: PEG-Intron®
In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
Also known as: REBETOL®
Number of Participants Who Relapsed At End of LTFU Year 5
Relapse was defined as Hepatitis C Virus ribonucleic acid (HCV-RNA) that was above the lower limit of quantitation at Year 5 of the LTFU.
Time frame: Part 2 LTFU Year 5
Mean Height Percentiles of Participants Over LTFU
To determine long-term effects of the Part 1 treatment on height, changes in height during the Part 2 LTFU were evaluated using height percentiles based on 2000 Center For Disease Control growth charts for the general population.
Time frame: Part 1 Pre-treatment Baseline, Part 2 LTFU Year 1, Part 2 LTFU Year 2, Part 2 LTFU Year 3, Part 2 LTFU Year 4, Part 2 LTFU Year 5, Last Available LTFU Visit (up to 5 years)
Mean Weight Percentiles of Participants Over LTFU
To determine long-term effects of the Part 1 treatment on weight, changes in weight during the Part 2 LTFU were evaluated using weight percentiles based on 2000 Center For Disease Control growth charts for the general population.
Time frame: Part 1 Pre-treatment Baseline, Part 2 LTFU Year 1, Part 2 LTFU Year 2, Part 2 LTFU Year 3, Part 2 LTFU Year 4, Part 2 LTFU Year 5, Last Available LTFU Visit (up to 5 years)
Mean Body Mass Index (BMI) Percentiles of Participants Over LTFU
To determine long-term effects of the Part 1 treatment on BMI, changes in BMI during the Part 2 LTFU were evaluated using BMI percentiles based on 2000 Center For Disease Control growth charts for the general population.
Time frame: Part 1 Pre-treatment Baseline, Part 2 LTFU Year 1, Part 2 LTFU Year 2, Part 2 LTFU Year 3, Part 2 LTFU Year 4, Part 2 LTFU Year 5, Last Available LTFU Visit (up to 5 years)
Mean Age at Attained Tanner Stages (Sexual Maturity) at End of LTFU (Last Observation) By Gender
The Tanner Stage (TS) defines physical measurements of sexual development based on external primary and secondary sex characteristics. Female participants are evaluated for breast development and pubic hair distribution and male participants are evaluated for genital development and pubic hair distribution, based on a 5-stage ordinal scale ranging from TS 1 (prepubertal/preadolescent characteristics) to TS 5 (mature or adult characteristics). Mean ages for attaining each TS in the normal population have been previously established based on measuring correlating reproductive hormone levels, and are expressed in years as follows for females (F) and males (M): TS 1= 7.1 (F+M); TS 2= 10.5 (F), 12.1 (M); TS 3= 11.6 (F), 13.6 (M); TS 4=, 12.3 (F), 15.1 (M); TS 5= 14.5 (F), 18 (M). To assess sexual maturation at the end of the LTFU (last observation), females and males were staged and the mean age at each TS attained was reported.
Time frame: Last assessment of the Part 2 LTFU (up to 5 years)
| Milestone | PEG-IFN + RBV: LTFU |
|---|---|
| Started | 94 |
| Completed | 80 |
| Not completed | 14 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Withdrawal by subject | 6 |
| Withdrew: Non-compliance with protocol | 1 |
| Withdrew: Administrative | 1 |
Relapse was defined as Hepatitis C Virus ribonucleic acid (HCV-RNA) that was above the lower limit of quantitation at Year 5 of the LTFU.
| participants | PEG-IFN + RBV: LTFU (All) |
|---|---|
| Number of Participants Who Relapsed At End of LTFU Year 5 | 0 |
To determine long-term effects of the Part 1 treatment on height, changes in height during the Part 2 LTFU were evaluated using height percentiles based on 2000 Center For Disease Control growth charts for the general population.
| percentile | PEG-IFN + RBV: LTFU (24 Weeks) | PEG-IFN + RBV: LTFU (48 Weeks) |
|---|---|---|
| Part 1 Pre-treatment Baseline | 48.94 ± 27.38 | 52.5 ± 29.98 |
| LTFU Year 1 (n=40, n=44) | 49.21 ± 29.03 | 43.37 ± 27.87 |
| LTFU Year 2 (n=39, n=39) | 50.56 ± 29.18 | 46.24 ± 29.19 |
| LTFU Year 3 (n=39, n=44) | 48.05 ± 28.38 | 46.00 ± 28.24 |
| LTFU Year 4 (n=40, n=38) | 49.62 ± 30.87 | 45.27 ± 29.44 |
| LTFU Year 5 (n=38, n=42) | 47.61 ± 29.57 | 43.51 ± 27.57 |
| Last Available LTFU Visit (n=46, n=48) | 45.96 ± 30.45 | 43.56 ± 27.19 |
To determine long-term effects of the Part 1 treatment on weight, changes in weight during the Part 2 LTFU were evaluated using weight percentiles based on 2000 Center For Disease Control growth charts for the general population.
| percentile | PEG-IFN + RBV: LTFU (24 Weeks) | PEG-IFN + RBV: LTFU (48 Weeks) |
|---|---|---|
| Part 1 Pre-treatment Baseline | 52.5 ± 26.83 | 58.56 ± 30.56 |
| LTFU Year 1 (n=40, n=44) | 53.62 ± 26.75 | 56.38 ± 30.55 |
| LTFU Year 2 (n=39, n=39) | 51.73 ± 26.89 | 52.03 ± 30.47 |
| LTFU Year 3 (n=39, n=44) | 53.18 ± 29.12 | 54.26 ± 30.37 |
| LTFU Year 4 (n=40, n=38) | 51.75 ± 28.90 | 49.50 ± 30.37 |
| LTFU Year 5 (n=38, n=42) | 51.16 ± 27.16 | 53.12 ± 31.38 |
| Last Available LTFU Visit (n=46, n=48) | 50.15 ± 28.44 | 55.53 ± 30.67 |
To determine long-term effects of the Part 1 treatment on BMI, changes in BMI during the Part 2 LTFU were evaluated using BMI percentiles based on 2000 Center For Disease Control growth charts for the general population.
| percentile | PEG-IFN + RBV: LTFU (24 Weeks) | PEG-IFN + RBV: LTFU (48 Weeks) |
|---|---|---|
| Part 1 Pre-treatment Baseline | 50.4 ± 29.63 | 59.76 ± 31.52 |
| LTFU Year 1 (n=40, n=44) | 51.15 ± 30.27 | 59.91 ± 31.55 |
| LTFU Year 2 (n=39, n=39) | 48.11 ± 29.59 | 52.89 ± 30.82 |
| LTFU Year 3 (n=39, n=44) | 52.14 ± 31.00 | 54.96 ± 30.89 |
| LTFU Year 4 (n=40, n=38) | 48.44 ± 30.46 | 48.69 ± 31.52 |
| LTFU Year 5 (n=38, n=42) | 48.61 ± 29.72 | 52.34 ± 31.87 |
| Last Available LTFU Visit (n=46, n=48) | 48.79 ± 29.40 | 55.38 ± 31.48 |
The Tanner Stage (TS) defines physical measurements of sexual development based on external primary and secondary sex characteristics. Female participants are evaluated for breast development and pubic hair distribution and male participants are evaluated for genital development and pubic hair distribution, based on a 5-stage ordinal scale ranging from TS 1 (prepubertal/preadolescent characteristics) to TS 5 (mature or adult characteristics). Mean ages for attaining each TS in the normal population have been previously established based on measuring correlating reproductive hormone levels, and are expressed in years as follows for females (F) and males (M): TS 1= 7.1 (F+M); TS 2= 10.5 (F), 12.1 (M); TS 3= 11.6 (F), 13.6 (M); TS 4=, 12.3 (F), 15.1 (M); TS 5= 14.5 (F), 18 (M). To assess sexual maturation at the end of the LTFU (last observation), females and males were staged and the mean age at each TS attained was reported.
| years | PEG-IFN + RBV: LTFU (Female) | PEG-IFN + RBV: LTFU (Male) |
|---|---|---|
| Age of TS 1 participants (n=4, n=5) | 9.75 ± 1.13 | 11.00 ± 0.80 |
| Age of TS 2 participants (n=5, n=3) | 11.86 ± 0.78 | 12.53 ± 1.27 |
| Age of TS 3 participants (n=7, n=1) | 15.26 ± 4.64 | 13.60 ± 0 |
| Age of TS 4 participants (n=4, n=6) | 16.00 ± 4.31 | 14.75 ± 1.47 |
| Age of TS 5 participants (n=21, n=27) | 17.37 ± 2.71 | 19.18 ± 2.48 |
Collected over 5 years, starting after the Part 1 post-treatment Follow-up Week 24 visit. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG-IFN + RBV: LTFU | — | 3/94 (3.2%) | — |
| Event | PEG-IFN + RBV: LTFU |
|---|---|
| AppendicitisInfections and infestations | 2/94 |
| TalipesCongenital, familial and genetic disorders | 1/94 |
| Age, Continuous(years) | PEG-IFN + RBV: LTFU |
|---|---|
| Mean | 9.9 ± 3.9 |
| Sex: Female, Male(Participants) | PEG-IFN + RBV: LTFU |
|---|---|
| Female | 49 |
| Male | 45 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Jul 2007, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin